BRIEF—Ensoma closes Series B extension, bringing total round to $135 million

Boston, USA-based genomic medicines firm Ensoma today announced the closing of an extension of its Series B financing by $50 million, bringing the total size of the funding round to $135 million.

The $50 million was contributed by new investors Kite, a Gilead Sciences subsidiary, Bioluminescence Ventures and Delos Capital and by existing investor SymBiosis.

These investors joined a syndicate of leading healthcare funds to advance the development of Ensoma’s Engenious in vivo engineered cell therapy p //latform and pipeline of genomic medicines for immuno-oncology, genetic disease and other therapeutic applications.

“Ensoma is creating a new generation of smart immune cell medicines by harnessing the concerted power of multiple immune cell types,” said Emile Nuwaysir, chief executive of Ensoma.

“There are millions of patients that need better answers. With this financing, we are well positioned to bring our breakthrough therapies to the clinic,” he added.